Microchip Based Isolation and Drug Delivery of Patient-Derived Extracellular Vesicles Against Their Homologous Tumor.

Autor: Ge K; Department of Hepatopancreatobiliary Surgery, Hangzhou First People's Hospital Affiliated to Medical School of Westlake University, Hangzhou, 310006, China.; Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, 362000, China., Ren Y; Department of Chemistry, Zhejiang University, Hangzhou, 310058, China., Hong Z; Department of Chemistry, Zhejiang University, Hangzhou, 310058, China., Mao Z; Department of Chemistry, Zhejiang University, Hangzhou, 310058, China., Yao B; Department of Chemistry, Zhejiang University, Hangzhou, 310058, China., Ye K; Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, 362000, China., Jia C; Department of Hepatopancreatobiliary Surgery, Hangzhou First People's Hospital Affiliated to Medical School of Westlake University, Hangzhou, 310006, China.
Jazyk: angličtina
Zdroj: Advanced healthcare materials [Adv Healthc Mater] 2024 Dec; Vol. 13 (30), pp. e2401990. Date of Electronic Publication: 2024 Sep 02.
DOI: 10.1002/adhm.202401990
Abstrakt: Extracellular vesicles (EVs) have demonstrated significant potential in drug delivery and anti-tumor therapy. Despite this promising strategy, challenges such as specific targeting, EVs purification persist. In this study, a personalized nanodrug delivery platform using patient-derived tumor EVs (PT-EVs) based on a microchip is presented. The microchip integrates multiple functions, including capture, enrichment, drug loading, and elution of PT-EVs. The isolation and drug-carrying procedures are completed within a 12 h timeframe, achieving a recovery rate of 65%, significantly surpassing the conventional ultracentrifuge (UC) method. Furthermore, PT-EVs derived from patient tumor models are first utilized as natural drug carriers, capitalizing on their inherent homing ability to precisely target homologous tumors. Lenvatinib and doxorubicin (DOX), two commonly utilized drugs in the clinical treatment of hepatocellular carcinoma (HCC), are loaded into PT-EVs and delivered to a matched in vitro tumor model that recapitulates original tumors for drug susceptibility testing. As is proven, PT-EVs exhibit robust tumor cell targeting and efficient receptor-mediated cellular uptake, and the efficacy of chemotherapeutic drugs is improved significantly. These results suggest that this platform could be a valuable tool for efficient isolation of PT-EVs and personalized drug customization, particularly when working with limited clinical samples, thus supporting personalized and precision medicine.
(© 2024 Wiley‐VCH GmbH.)
Databáze: MEDLINE
Externí odkaz: